07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Cangen, Dai Nippon Printing Co. Ltd. deal

Cangen received an undisclosed milestone from Dai Nippon under a March 2007 deal to develop and commercialize a blood-based diagnostic for early stage lung cancer. The payment was triggered by demonstration of proof-of-concept. Under the...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Company News

Cangen, Olympus Corp. deal

The companies expanded their 2005 deal to develop a DNA- and protein-based diagnostic for lung cancer (see BioCentury, May 30, 2005). Olympus now will fund a clinical trial of the test. Cangen Biotechnologies Inc. ,...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

Cangen, Olympus Corp. deal

The companies will collaborate to develop a DNA- and protein-based diagnostic for lung cancer. Cangen will use Olympus' microarray technology for the DNA-based portion of the test. Cangen Biotechnologies Inc. , Bethesda, Md.   Olympus...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Clinical News

Microsatellite DNA test: Phase III started

Cangen began a Phase III trial in 300 patients. Cangen Biotechnologies Inc. , Bethesda, Md.   Product: Microsatellite DNA test   Business: Diagnostic   Molecular target: NA   Description: Identifies genetic alterations in microsatellite DNA...